DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September:

Baird 2026 Global Healthcare Conference (NYC)

Date: Tuesday, September 15, 2026
Format: Fireside Chat & 1×1 and Group Meetings
Time: 2:00 -2:30 PM EDT
Webcast: FTRE Baird Webcast

Deutsche Bank 2026 Healthcare Summit (NYC)

Date: Wednesday, September 16, 2026
Format: 1×1 and Group Meetings

RBC Pharma Services and Life Science Tools Virtual Conference

Date: Tuesday, September 22, 2026
Format: 1×1 and Group Meetings

The live webcast and replay of the Baird fireside chat will be accessible through the “Events” section of Fortrea’s Investor Relations website. Investors interested in meeting with management should contact their banking representatives.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

Fortrea Contacts

Tracy Krumme (Investors) – 984-385-6707, tracy.krumme@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com

SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that financial advisor Jeneen Slack, CFP®, CDFA®, founder and partner of Northstar Financial Advisors, LLC, has joined LPL Financial’s broker-dealer and Registered Investment Advisor (RIA) platform. Slack reported serving more than $270 million in client assets* and joins LPL from Raymond James.

With nearly 20 years of industry experience, Slack built her practice on a belief that financial advice is most impactful when it is rooted in strong personal relationships. Initially inspired by a desire to help women feel more confident discussing and managing their finances, her approach today is centered on helping individuals and families make informed decisions about their financial futures.

Based in Danville, Calif., Slack serves a diverse clientele throughout the Bay Area, including professionals, families, retirees and individuals navigating major life transitions. As a Certified Divorce Financial Analyst (CDFA®), she specializes in helping clients understand the financial implications of divorce and supporting their long-term planning needs beyond the process itself.

“Relationships are truly at the heart of everything we do at Northstar,” Slack said. “We’ve intentionally built a personalized service model where every member of our team knows our clients personally and understands what matters most to them. Whether we’re helping someone navigate retirement, prepare a child for financial independence or make complex decisions during a divorce, our goal is to provide guidance that evolves alongside our clients’ lives.”

Slack, along with her business partner and fellow financial advisor Eric Slack, is supported by Kari Jeha, Jon Lee and V. John Threlkeld. Together, they bring decades of combined industry experience and a hands-on approach focused on delivering individualized service. Beyond working with clients, the practice is deeply committed to community engagement – regularly hosting educational workshops, retirement planning programs and client events designed to foster deeper connections and financial literacy.

Why Northstar Financial Advisors Chose LPL

As she looked ahead to the next chapter of her career, Slack sought a partner that would give her the flexibility to build Northstar around her vision for the future while providing the scale and resources of a leading financial services firm. She was particularly attracted to LPL’s commitment to innovation, its advanced technology capabilities and the depth of support available to established advisors.

“I’m at a point in my career where I wanted a partner that is continually investing in the future of advice,” Slack said. “LPL gives us the flexibility and resources to operate the way we believe is best for our clients, while providing the technology and support to help our team work more efficiently. That combination allows us to focus on what matters most — delivering thoughtful, personalized guidance and maintaining the strong relationships we’ve built with our clients.”

Marc Cohen, Chief Growth Officer at LPL Financial, said, “What Jeneen has built at Northstar is personal by design. She and her team take the time to know their clients, helping women engage more confidently with their finances and guiding individuals and families through the decisions and transitions that shape their lives. We are honored that Jeneen chose LPL for Northstar’s next chapter and look forward to helping the team extend that experience to more clients.”

Related

Advisors, learn how LPL Financial can help take your business to the next level.

About LPL Financial

LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 32,000 financial advisors and the wealth management practices of approximately 1,100 financial institutions, servicing and custodying approximately $2.6 trillion in brokerage and advisory assets on behalf of approximately 8 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment advisor and broker-dealer, member FINRA/SIPC. Northstar Financial Advisors and LPL Financial are separate entities.

LPL Financial does not offer tax advice or tax preparation services.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

*Value approximated based on asset and holding details provided to LPL from end of year, 2025.

Media Contact: 
Media.relations@LPLFinancial.com  

Tracking #1171024

Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027

Up to 200 participants at sites across Canada, among the largest studies of naturally derived psilocybin to date

VANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (Nasdaq: OPTH) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with major depressive disorder (“MDD“). The trial is planned to be initiated in the first half of 2027, with dosing expected to be complete by the end of 2027.

The Phase 2 clinical trial is authorized to proceed by Health Canada and will enroll up to 200 participants across multiple sites in Canada, evaluating the safety and efficacy of a single supervised dose of natural psilocybin in the treatment of MDD. The primary efficacy endpoint is the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline, the most widely used clinician-rated measure of depressive symptom severity in trials of this kind.

“A 200-subject Phase 2 trial in major depressive disorder is the largest clinical commitment Optimi has made to date. We will supply our own naturally derived psilocybin, manufactured at our GMP facility, and we will have exclusive ownership of the trial results,” said Dane Stevens, Optimi Chief Executive Officer and Co-Founder. “As we broaden our strategy to include clinical drug development, this Phase 2 trial is an initial step toward potential registration. Few companies in this sector are commercial today while also advancing their own clinical development. In Canada, we already hold a Drug Establishment Licence and supply psilocybin through Health Canada’s Special Access Program. This trial builds directly on that foundation, and we can comfortably fund it with current cash on hand.”

The clinical trial is set to be one of the largest clinical studies of naturally derived psilocybin to date, and will include periodic interim safety and efficacy readouts, with full topline results available after dosing and follow-up evaluations are completed for all 200 participants.

MDD is among the most common mental health conditions worldwide, affecting an estimated 332 million people, according to the World Health Organization.1 A substantial proportion of patients do not respond adequately to existing antidepressant treatments, which typically require weeks of continuous use before clinical benefits emerge.

1World Health Organization, Depressive disorder (depression) fact sheet, 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/depression

The safety and efficacy of psilocybin assisted therapy to treat MDD is still under investigation and none of Optimi’s psilocybin drug products received market authorization by Health Canada.

About Optimi Health Corp.

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

For more information, please visit optimi.net.

For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca

Investor Relations Contact:
CORE IR
ir@optimi.net

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the proposed clinical trial, the availability and enrolment of patients in the trial, the utilization of the data derived from the trial, and the ability to conduct evaluations as part of the trial, the Company’s ability to manufacture and ship products from its Canadian facility, and the Company’s positioning in the regulated psychedelic medicine market. Forward-looking statements and forward-looking information are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “estimates,” “may,” “will,” “would,” “could,” or similar expressions. Forward-looking statements and forward-looking information are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under “Risk Factors” in the Company’s registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at www.sec.gov and on SEDAR+ at www.sedarplus.ca and in the Company’s continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. These forward-looking statements reflect current expectations of management regarding future events and speak only as of the date of this press release. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

VANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (the “Company or Cannabix”) developer of marijuana and alcohol breath testing technologies, is pleased to announce the deployment of its BreathLogix alcohol monitoring solution with the Lake County Community Corrections Program in Indiana. Lake County is Indiana’s second-most populous county, serving residents in the greater Chicago metropolitan region.

The BreathLogix system will support court-ordered alcohol monitoring initiatives administered by Lake County’s community corrections program staff. The deployment is designed to assist program administrators in monitoring participant compliance with court-imposed abstinence requirements while improving operational efficiency and reducing administrative burden.

Under the program, participants are required to undergo scheduled or random alcohol testing as a condition of probation, treatment, pre-trial release, or other court-supervised programs. The deployment is being facilitated by AlcoPro, Inc., an authorized reseller.

Under the program, participants may be required to undergo scheduled or random alcohol testing as a condition of probation, diversion, treatment, pre-trial release, or other court-supervised programs. BreathLogix enables participants to provide breath samples autonomously while maintaining identity verification through integrated photo capture technology.

BreathLogix rapidly screens for alcohol using a breath sample while simultaneously capturing a photograph of the user for identity verification. The system provides precise Blood Alcohol Content (BAC / BrAC) readings and can automatically deliver real-time alerts via SMS and email to designated program administrators when positive results are detected.

The deployment further expands Cannabix’s presence within the U.S. corrections, probation, treatment, and public safety markets where organizations are seeking automated alcohol testing solutions that improve compliance oversight while reducing staffing requirements.

BreathLogix Alcohol device available with for County Sobriety Programs

Figure 1. BreathLogix Alcohol device available with for County Sobriety Programs

BreathLogix supports a broad range of alcohol monitoring applications, including:

  • Court-ordered alcohol monitoring
  • Probation and parole programs
  • Pre-trial release supervision
  • Diversion and specialty court programs
  • Treatment and recovery programs
  • Random and scheduled alcohol testing
  • Workplace and safety-sensitive screening
  • Return-to-work and fitness-for-duty assessments

By enabling frequent, reliable and automated alcohol screening, BreathLogix helps courts, treatment providers and supervision agencies strengthen compliance monitoring, improve participant accountability and enhance public safety outcomes.

Marketing Agreement

The Company has entered into a marketing services agreement (the “Agreement”) with Outside the Box Capital Inc. (“OTBC”), an arm’s-length marketing firm based in Oakville, Ontario. Pursuant to the Agreement, OTBC will provide marketing services, including social media marketing, content planning and creation, and the production and distribution of feature content regarding the Company through OTBC’s proprietary media channels and selected third-party platforms. The Agreement is effective September 9, 2026, for a term of six months. In consideration for the services to be provided under the Agreement, the Company has agreed to pay OTBC a one-time cash fee of $150,000 plus applicable taxes and 335,000 stock options (the “Options”) to acquire common shares of the Company at an exercise price of $0.45 per share for a period of one year from the date of grant. The Options will vest in accordance with the policies of the Canadian Securities Exchange and the Company’s equity incentive plan. Any common shares issued upon the exercise of the Options will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws.

OTBC is controlled by Jason Coles. OTBC and Mr. Coles are arm’s-length parties to the Company. Other than the Options described above, neither OTBC nor Mr. Coles currently holds any direct or indirect interest in the Company or its securities. OTBC has no relationship with the Company other than pursuant to the Agreement described in this news release.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leading developer of breath-based technologies designed to enhance public safety and reduce impairment-related risks in a range of different settings. The Marijuana Breath Test (MBT) targets delta-9 THC—the primary psychoactive compound in cannabis—in breath, providing a practical solution for identifying recent marijuana use.

The BreathLogix, unmanned alcohol screening solution supports organizations in proactively monitoring alcohol impairment, strengthening safety protocols, and promoting responsible behavior. By delivering innovative, non-invasive screening tools, Cannabix aims to help reduce accidents, improve decision-making, and protect organizations, individuals and the public at large. Visit www.cannabixtechnologies.com

We seek Safe Harbor.
On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains certain “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “may,” “will,” “could,” “should,” “potential,” and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements regarding: the anticipated benefits, performance and adoption of the Company’s BreathLogix alcohol monitoring system; the expected use of the system by community corrections agencies and other public sector organizations; the Company’s ability to expand deployments of BreathLogix in the United States and other jurisdictions; the commercialization and market acceptance of the Company’s products and technologies; the Company’s ability to enter into additional customer, distribution, service, or strategic partnership agreements; and the Company’s ongoing business, product development and financing plans. Forward-looking statements are based on management’s current expectations, assumptions and beliefs and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Such factors include, without limitation: the ability of the Company to successfully deploy and support its technologies; customer adoption and retention; regulatory developments; changes in government procurement practices or community corrections requirements; competitive developments; technological advancements by competitors; economic and market conditions; the availability of financing; and other risks detailed from time to time in the Company’s public disclosure documents. There can be no assurance that the Company’s products will achieve commercial acceptance, that existing deployments will lead to additional contracts or revenue opportunities, or that any anticipated business objectives, strategic initiatives, partnerships, or growth opportunities will be realized. Actual results may differ materially from those currently anticipated in such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and are based on the beliefs, estimates, expectations and opinions of management on the date such statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c280215e-c351-42df-b85c-5f581f46994e

 

Bank of Åland Plc
Stock exchange release
September 10, 2026, 15.45 EEST

Bank of Åland Plc to increase prime rate

The Bank of Åland Plc (Ålandsbanken Abp) has decided to increase its prime rate by 0.25 percentage points, from 2.25 per cent to 2.50 per cent. The basis for this decision is rising market interest rates. The change goes into effect on September 24, 2026.

Bank of Åland Plc

For further information, please contact:
Peter Wiklöf, Managing Director and Chief Executive, Bank of Åland Plc, tel +358 40 512 7505

Company will hold a formal presentation and one-on-one investor meetings September 14-16, 2026

MBody AI

ISFIYA, Israel and LAS VEGAS, Sept. 10, 2026 (GLOBE NEWSWIRE) — MBody AI Ltd. (“MBody AI” or the “Company”) (NASDAQ: MBAI) today announced that John Fowler, Chief Executive Officer and Tim Hayden, Chief Financial Officer of MBody AI, will present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.

In addition to the formal presentation which will be available On-Demand, management will be available for one-on-one investor meetings during the conference. Investors interested in scheduling a one-on-one meeting with management during the conference should contact their H.C. Wainwright representative or meetings@hcwco.com or Lytham Partners at 602-889-9700 or ir@mbody.ai.

MBody AI’s Orchestrator is a proprietary, hardware-agnostic software platform that serves as an intelligence layer designed to enable autonomous systems to operate, coordinate, and improve more effectively than they otherwise would in real-world physical environments. It is designed as a full-stack embodied AI software system that integrates multiple functional components intended to support autonomous operation and fleet-level coordination.

The two core features of Orchestrator are AI Optimization, Task Verification and Reporting. AI Optimization uses artificial intelligence to assess telemetry and run-time data and generate recommendations to improve performance against customer key performance indicators, across a customer’s fleet regardless of brand.

Task Verification and Reporting provides unified dashboarding and reporting across a customer’s full fleet and multiple robot types, including verification that assigned tasks have been completed.

Learn more about MBody AI’s growth trajectory at ir.mbody.ai

About H.C. Wainwright & Co.

H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory, sales & trading, research, and related services to public and private growth companies across multiple focuses and regions. The HCW team has been the leader in the CMPO (confidentially marketed public offerings), RD (registered direct offering) and PIPE (private investment in public equity) transaction markets since 1998.

About MBody AI Ltd.

MBody AI Ltd. (NASDAQ: MBAI) develops enterprise software that deploys and manages autonomous robot workforces for hospitality and gaming operators. The Company’s proprietary MBody AI Orchestrator is a hardware-agnostic software platform that manages diverse robot fleets from multiple vendors across sites and use cases under long-term agreements. MBody AI counts Fortune 500 operators among its customers.

No Offer or Solicitation

This press release does not constitute an offer to sell or a solicitation of an offer to buy, and shall not constitute an offer, solicitation, or sale in any state, province, territory, or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements made in graphics, images, headlines, and other visual elements of this release. All statements other than statements of historical fact are forward-looking statements, which include, among others, statements regarding the expected performance, functionality, and capabilities of the MBody AI Orchestrator platform; the Company’s technology roadmap; the Company’s expectation that operational data generated by its deployments will refine its models and improve platform performance over time; the Company’s deployment pipeline, customer expansion, and commercial scaling; the anticipated growth of the embodied AI market; the Company’s ability to maintain continued compliance with Nasdaq listing requirements; and the Company’s continued qualification as a foreign private issuer. These forward-looking statements are based on the Company’s current intentions, beliefs, and expectations regarding future events. Actual results may differ materially due to risks and uncertainties including, but not limited to, the risk that the multi-brand fleet control capability does not complete testing or is not deployed with customers on the anticipated timeline or at all; the risk that the customer-systems integration capability is never completed or made available, and that the related provisional patent applications do not result in issued patents; the risk that the platform does not perform as designed or that operational data does not yield the expected improvements; customer concentration risk, the Company being substantially dependent on two enterprise customers; the Company’s ability to convert pilot deployments into contracted revenue; the risk that the Company fails to satisfy Nasdaq continued listing standards, including the minimum bid price and shareholders’ equity requirements; the risk that the Company ceases to qualify as a foreign private issuer and becomes subject to domestic reporting requirements; the Company’s need for additional capital and the dilutive effect of any financing; market conditions; and other factors described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by law.

Quick Facts

Issuer: MBody AI Ltd. (NASDAQ: MBAI)
Listing: Nasdaq Capital Markets
Sector: Technology
Industry: Embodied AI and enterprise robotics (physical AI)
Event: H.C. Wainwright 28th Annual Global Investment Conference
Date: September 14-16, 2026
Location: Lotte New York Palace Hotel, New York City
CUSIP M6S83C106

Investor Relations:
Lytham Partners, LLC
602-889-9700
ir@mbody.ai

Media Contact:
Core IR
ir@mbody.ai

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1633c2e1-2003-4789-b023-5900f7374b46

DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will participate in the upcoming HC Wainwright 28th Annual Global Investment Conference being held September 14 to 16, 2026 in New York City.

The SeaStar Medical presentation will be available on September 11, 2026, at 7:00 am Eastern Time and can be accessed by visiting the Events & Presentations page, located under the Investor Relations section of the SeaStar Medical website. The presentation will be available for 60 days following the event.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Contact:
IR@SEASTARMED.COM

Management to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth Conference and the H.C. Wainwright 28th Annual Global Investment Conference in September 2026

CORSICANA, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) — Birchtech Corp. (NYSE American: BCHT) (TSX: BCHT) (“Birchtech” or the “Company”), a leader in specialty activated carbon technologies for sustainable air and water treatment, today announced that management will participate in two upcoming investor conferences: Lake Street Capital Markets’ 10th Annual Best Ideas Growth Conference and the H.C. Wainwright 28th Annual Global Investment Conference.

Richard MacPherson, President and CEO of Birchtech, is scheduled to host one-on-one meetings with institutional investors at each event, and will deliver a corporate presentation at the H.C. Wainwright conference, as follows:

Lake Street Capital Markets’ 10th Annual Best Ideas Growth Conference
Conference Date: September 10, 2026
Location: The Metropolitan Club, New York, NY
Format: 1×1 Meetings Only

H.C. Wainwright 28th Annual Global Investment Conference
Conference Dates: September 14-16, 2026
Location: Lotte New York Palace Hotel, New York, NY
Format: Presentation & 1×1 Meetings
Presentation Date: September 14, 2026
Presentation Time: 1:00 PM Eastern Time
Webcast: https://journey.ct.events/view/06c774a5-563e-4cc8-b69e-5ae9d31b6e7c

A live audio webcast and archive of the H.C. Wainwright presentation will be available using the webcast link above. For more information or to schedule a meeting with management, please contact MZ Group at BCHT@mzgroup.us.

About Birchtech Corp.

Birchtech Corp. (NYSE American: BCHT) (TSX: BCHT) is a leader in specialty activated carbon technologies delivering innovative solutions for air and water purification to support a cleaner, more sustainable future. The Company provides patented SEA® sorbent technologies for mercury emissions capture for the coal-fired utility sector and SEA disruptive water purification technologies with a specialization on removing contaminants, including ‘forever chemicals’ such as PFAS, from potable water and industrial wastewater. Backed by a strong intellectual property portfolio and a team of activated carbon experts, Birchtech provides cleaner air to North American communities and is applying this expertise to a novel approach in water purification. To learn more, please visit www.birchtech.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward-looking statements” that are made pursuant to the Safe Harbor Provisions of the U.S. Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are generally identified by using words such as “anticipate,” “believe,” “plan,” “expect,” “intend,” “will,” and similar expressions, but these words are not the exclusive means of identifying forward-looking statements. Forward-looking statements in this release include statements relating to expected developments and growth in Birchtech’s business, as well as anticipated investor engagements and the Company’s participation in investor conferences. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. In addition, this release contains time-sensitive information that reflects management’s best analysis only as of the date of this release. Birchtech does not undertake any obligation to publicly update or revise any forward-looking statements to reflect future events, information or circumstances that arise after the date of this release. Further information concerning issues that could materially affect financial performance or other forward-looking statements contained in this release can be found in Birchtech’s periodic filings with the Securities and Exchange Commission or Canadian securities regulators.

Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group – MZ North America
(949) 259-4987
BCHT@mzgroup.us
www.mzgroup.us

CULVER CITY, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games”), a leading independent global developer and publisher of interactive digital entertainment, today announced it will be presenting and holding one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14-16, 2026, at the Lotte New York Palace Hotel, New York City.

Snail Games’ management is scheduled to present on Monday, September 14, 2026, at 4:00 p.m. Eastern time. Snail Games’ management will also be available for one-on-one meetings during the conference. 

The presentation will be available for viewing online via webcast here.

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

About H.C. Wainwright & Co.
H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors.
For more information visit H.C. Wainwright & Co. at www.hcwco.com.

Snail, Inc. Investor Relations:
Gateway Group, Inc.
John Yi and Steven Shinmachi
949-574-3860
SNAL@gateway-grp.com

Gen-Tracker’s universal, automatic transfer switch (ATS)-based monitoring technology and veteran team extend OmniMetrix’s reach to standby generators of virtually any make, model or age

OAKDALE, Minn. and BUFORD, Ga., Sept. 10, 2026 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (Nasdaq: ACFN), a provider of remote monitoring and control solutions for critical infrastructure, today announced that its OmniMetrix subsidiary has acquired substantially all of the assets of Generator Solutions, Inc., a provider of remote monitoring systems for standby generators under the “Gen-Tracker” brand name, effective September 9, 2026.

Generator Solutions is one of the longest-standing independent generator monitoring providers, with approximately $1.1M in recurring annual monitoring revenue and $400,000 in annual monitoring equipment sales. Since its founding in St. Paul, Minnesota in 2001, Generator Solutions has established Gen-Tracker as one of the most respected monitoring platforms in the commercial and industrial standby generator market.

Agreement Terms
Pursuant to the asset purchase agreement, OmniMetrix paid $1.0M in cash at closing and agreed to make additional cash payments of $450,000 per year, for each of the next four years, and a final payment of $700,000 in the fifth year, for total consideration of $3.5M. Acquired assets include the company’s customer accounts, dealer relationships, trade names, trademarks, technology, accounts receivables and hardware inventory.

Every full-time Generator Solutions employee has joined OmniMetrix and will continue to work from the existing Minnesota location. The team brings decades of combined, hands-on experience in standby power, automatic transfer switch (ATS) integration and generator dealer support.

Two Complementary Approaches, One Provider
Generator Solutions has historically competed with OmniMetrix in the commercial and industrial standby generator monitoring market, and its flagship Gen-Tracker product takes a fundamentally different path to the same goal. Rather than connecting to the generator’s engine controller, Gen-Tracker monitors generator readiness through the ATS –– a design that works across generators of virtually any make, model, or age, including the large installed base of older units that predate modern controllers.

Combined with OmniMetrix’s controller-level, enterprise-grade platform, the two approaches give dealers and end customers a single source for:

  • Deep diagnostics on modern, controller-equipped generators
  • Universal readiness monitoring on legacy, orphaned and mixed-brand fleets
  • One provider and one support organization for a facility portfolio, regardless of what’s behind the door

CEO Commentary
Acorn and OmniMetrix CEO, Jan Loeb, commented, “Gen-Tracker is a proven, first-class solution that builds on our capabilities and market leadership, while extending our service reach. By combining our controller-level and enterprise-grade monitoring with Gen-Tracker’s ATS-based universal monitoring approach, we can now serve a broader range of customers and generator environments than either company could alone.

“Importantly, we’re adding a team that has spent 25 years in this market, bringing deep expertise in transfer switches, field installation, and dealer support to make OmniMetrix an even stronger partner to every customer we serve.

“Based on OmniMetrix’s first half monitoring revenue of $2.8M, we expect the acquisition to increase annualized monitoring revenue by at least 15%. We also expect the transaction to be accretive to our 2027 net income by at least $0.10 per diluted share.

“After an extended process of dialogue and evaluation, we are excited to welcome the Gen-Tracker operations to the OmniMetrix family, and we look forward to leveraging our collective strengths to drive continued growth across the business.”

About Acorn (www.acornenergy.com) and OmniMetrixTM (www.omnimetrix.net)
Acorn’s wholly-owned OmniMetrix subsidiary is a pioneer and leader in wireless remote monitoring and control solutions for standby generators, gas pipelines, and other infrastructure assets. Its recently-launched OMNI360 product line provides cutting-edge infrastructure management and security solutions for cell towers, data centers and utility networks. OmniMetrix serves tens of thousands of commercial and residential endpoints, including over 25 Fortune/Global 500 companies in sectors including telecom, manufacturing, healthcare, data centers, retail, public transportation, energy distribution and government facilities, as well as residential customers through generator dealers.

OmniMetrix’s industry-leading, cost-effective solutions make critical systems more reliable, provide security, and also enable automated “demand response” electric grid support via enrolled backup generators.

Safe Harbor Statement
This press release includes forward-looking statements, which are subject to risks and uncertainties. There are no assurances that Acorn will be successful in growing its business, increasing its revenue, increasing profitability, or maximizing the value of its operating company and other assets. A complete discussion of the risks and uncertainties that may affect Acorn Energy’s business, including the business of its subsidiary, is included in “Risk Factors” in the Company’s most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.

Follow us

X (formerly Twitter):
StockTwits:                   
@Acorn_IR and @OmniMetrix
@Acorn_Energy


Investor Relations Contacts
Catalyst IR
William Jones, 267-987-2082
David Collins, 212-924-9800
acfn@catalyst-ir.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.